購物車 
-
利托那韋
NMR and HPLC COA下載 MSDS下載 - Names：
Ritonavir
- CAS號：
155213-67-5
MDL Number： - MF(分子式)： C37H48N6O5S2 MW(分子量)： 720.3127601
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 貨品編碼 | 規格 | 純度 | 價格 (￥) | 現價(￥) | 特價(￥) | 庫存描述 | 數量 | 總計 (￥) |
|---|---|---|---|---|---|---|---|---|
| HCQ000017-250mg | 250mg | 99% | ￥ 2150.00 | ￥ 2150.00 | 1-2days Instock | ￥ 0.00 | ||
| HCQ000017-100mg | 100mg | 99% | ￥ 1420.00 | ￥ 1420.00 | 1-2days Instock | ￥ 0.00 | ||
| HCQ000017-25mg | 25mg | 99% | ￥ 480.00 | ￥ 480.00 | 1-2days Instock | ￥ 0.00 |
| 中文別名 | 瑞托那韋; 蛋白酶抑制劑; 利托那韋（cas,msds,應用） |
| 英文別名 | Ritonavir(155213-67-5) |
| CAS號 | 155213-67-5 |
| SMILES | CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1 |
| Inchi | 1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1 |
| InchiKey | NCDNCNXCDXHOMX-XGKFQTDJSA-N |
| 分子式 Molecular Weight | C37H48N6O5S2 |
| 分子量 Formula | 720.3127601 |
| 閃點 FP | |
| 熔點 Melting point | NA |
| 沸點 Boiling point | |
| Polarizability極化度 | |
| 密度 Density | |
| 蒸汽壓 Vapor Pressure | |
| 溶解度Solubility | DMSO 80 mg/mL |
| 性狀 | 固體粉末 |
| 儲藏條件 Storage conditions | -20°C,-4℃存儲 |
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
| 產品說明 | 利托那韋(CAS:155213-67-5,英文名:Ritonavir)屬于蛋白酶抑制劑類的抗逆轉錄病毒小分子化合物，利托那韋可用于治療HIV感染以及艾滋病。 |
| Introduction | Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulation and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as Paritaprevir and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as a first-line therapy for HCV Genotype 1a/b and 4 treatment-na?ve patients with or without cirrhosis. Ritonavir is found in a fixed-dose combination product with Ombitasvir, Dasabuvir, and Paritaprevir as the FDA-approved product Viekira Pak. First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis.Ritonavir is also available as a fixed-dose combination product with Ombitasvir and Paritaprevir as the FDA- and Health Canada-approved product Technivie. First approved in July 2015, Technivie is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis.In Canada, ritonavir is also available as a fixed-dose combination product with Ombitasvir, Dasabuvir, and Paritaprevir as the Health Canada-approved, commercially available product Holkira Pak. First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a with or without cirrhosis. Inclusion of ritonavir can can select for HIV-1 protease inhibitor resistance-associated substitutions. Any HCV/HIV-1 co-infected patients treated with ritonavir-containing combination therapies should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance. |
| Application1 | 潛在冠狀病毒抑制劑Experimental Unapproved Treatments for COVID-19 |
| Application2 | |
| Application3 |
Ritonavir (trade name Norvir) is an antiretroviral compound from the protease inhibitor class used to treat HIV infection and AIDS. Ritonavir (ABT-538) induces CYP 1A2 and inhibits the major P450 isoforms (3A4 and 2D6). Ritonavir is frequently prescribed with HAART, not for its antiviral action, but as it inhibits the same host enzyme that metabolizes other protease inhibitors, allowing the clinician to lower their dose and frequency and improving their clinical efficacy. More specifically, ritonavir (ABT-538) is used to inhibit a particular liver enzyme that normally metabolizes protease inhibitors, cytochrome P450-3A4 (CYP3A4). Ritonavir's inhibition of the cytochrome P-450 CYP3A4 enzyme reduces the metabolism of concomitantly administered protease inhibitors and changes their pharmacokinetic parameters, including area under the curve (AUC), maximum concentration (Cmax), minimum concentration (Cmin) and half-life (t1/2). As a result, the bioavailability of the boosted protease inhibitor is increased and improved penetration into HIV reservoirs may be achieved.
Ritonavir 是一種蛋白酶抑制劑類抗逆轉錄病毒化合物，用于治療HIV感染和艾滋病。利托那韋（ABT-538）誘導CYP 1A2并抑制主要的P450亞型（3A4和2D6）。 HAART經常與利托那韋一起開處方，并不是因為它具有抗病毒作用，而是因為它抑制與其他蛋白酶抑制劑代謝相同的宿主酶，從而使臨床醫生能夠降低其劑量和頻率并提高其臨床療效。更具體地說，利托那韋（ABT-538）用于抑制通常代謝蛋白酶抑制劑細胞色素P450-3A4（CYP3A4）的特定肝酶。利托那韋對細胞色素P-450 CYP3A4酶的抑制作用會降低同時給藥的蛋白酶抑制劑的代謝并改變其藥代動力學參數，包括曲線下面積（AUC），最大濃度（Cmax），最小濃度（Cmin）和半衰期（t1） / 2）。結果，增強的蛋白酶抑制劑的生物利用度得以提高，并且可以提高對HIV貯庫的滲透。
Ritonavir 是一種蛋白酶抑制劑類抗逆轉錄病毒化合物，用于治療HIV感染和艾滋病。利托那韋（ABT-538）誘導CYP 1A2并抑制主要的P450亞型（3A4和2D6）。 HAART經常與利托那韋一起開處方，并不是因為它具有抗病毒作用，而是因為它抑制與其他蛋白酶抑制劑代謝相同的宿主酶，從而使臨床醫生能夠降低其劑量和頻率并提高其臨床療效。更具體地說，利托那韋（ABT-538）用于抑制通常代謝蛋白酶抑制劑細胞色素P450-3A4（CYP3A4）的特定肝酶。利托那韋對細胞色素P-450 CYP3A4酶的抑制作用會降低同時給藥的蛋白酶抑制劑的代謝并改變其藥代動力學參數，包括曲線下面積（AUC），最大濃度（Cmax），最小濃度（Cmin）和半衰期（t1） / 2）。結果，增強的蛋白酶抑制劑的生物利用度得以提高，并且可以提高對HIV貯庫的滲透。
| Hull MW, Montaner JS: Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med. 2011 Aug;43(5):375-88. doi: 10.3109/07853890.2011.572905. Epub 2011 Apr 18. [PubMed:21501034] |
| Myers RP, Shah H, Burak KW, Cooper C, Feld JJ: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13. [PubMed:25585348] |
| Sevrioukova IF, Poulos TL: Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18422-7. doi: 10.1073/pnas.1010693107. Epub 2010 Oct 11. [PubMed:20937904] |
| Rock BM, Hengel SM, Rock DA, Wienkers LC, Kunze KL: Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4. Mol Pharmacol. 2014 Dec;86(6):665-74. doi: 10.1124/mol.114.094862. Epub 2014 Oct 1. [PubMed:25274602] |
| Tseng A, Hughes CA, Wu J, Seet J, Phillips EJ: Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences. Ann Pharmacother. 2017 Nov;51(11):1008-1022. doi: 10.1177/1060028017717018. Epub 2017 Jun 19. [PubMed:28627229] |
American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017. [Link]
FDA Approved Drug Products: NORVIR (ritonavir) Capsules, Soft Gelatin for Oral use [Link]
FDA Approved Drug Products: Norvir (ritonavir) for oral use [Link]
CaymanChem: Ritonavir MSDS [Link]
FDA Approved Drug Products: NORVIR (ritonavir) Capsules, Soft Gelatin for Oral use [Link]
FDA Approved Drug Products: Norvir (ritonavir) for oral use [Link]
CaymanChem: Ritonavir MSDS [Link]
對不起，暫無產品評價！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關產品
-
< >
- 推薦產品
-
< >
- 最新產品
-
< >
新聞
牛血清白蛋白（BSA）常見問題
牛血清白蛋白（BSA）常見問題:牛血清白蛋白（BSA）在實驗室中是通用的，可用于蛋白質印跡、細胞組織培養、P...
2022/10/19 9:39:51
pubmed使用方法(技巧)
pubmed使用方法(技巧)：PubMed是一個關于醫學問題的學術文章和書籍的數據庫。因為它是一份學術期刊，...
2022/10/18 18:06:07
BSA(牛血清白蛋白)
BSA(牛血清白蛋白):牛血清白蛋白（BSA）是一種球狀蛋白質，牛血清白蛋白（BSA）是發現于牛血漿中的主要...
2022/10/18 16:48:12
凍干培養細菌的方法
凍干培養細菌的方法：冷凍干燥，也稱為凍干或冷凍干燥，是在產品冷凍后除去水分并將其置于真空中的過程。這使得冰可...
2022/10/16 8:27:31
革蘭氏染色應用(原理,方法,步驟,優缺點)
微生物中的革蘭氏染色應用：革蘭氏染色是一種差異染色方法，用于根據細菌細胞壁的特性將細菌分為兩組（革蘭氏陽性和...
2022/10/16 8:10:57
支原體去除劑的使用方法,工作濃度,對細胞有影響嗎？
支原體去除劑的使用方法,工作濃度,對細胞有影響嗎？將支原體清除劑添加到被支原體污染的細胞培養物中，濃度建議為...
2022/10/13 9:24:46
DNA和染色體之間的差別
DNA和染色體之間的差別：DNA和染色體的關鍵區別在于其結構的組織。DNA是由脫氧核糖核苷酸組成的雙鏈螺旋聚...
2022/10/10 12:49:53
DNA分離和RNA分離的區別
DNA分離和RNA分離的區別:DNA和RNA分離的關鍵區別在于，DNA分離是從生物細胞中提取一種稱為DNA的...
2022/10/8 15:22:57
PMSF蛋白酶抑制劑使用中的常見問題
PMSF蛋白酶抑制劑使用中的常見問題:
2022/10/1 7:48:57
PMSF（苯甲基磺酰氟）
PMSF（苯甲基磺酰氟）：PMSF（苯甲基磺酰氟）是一種不可逆的絲氨酸蛋白酶抑制劑，用于各種研究和實驗室過程...
2022/9/30 22:18:04
